Site Alert

Claim & Account Center and Secure Message Center are currently experiencing intermittent slowdowns. We are working to resolve this issue as soon as possible. We apologize for any inconvenience.

Coverage Decisions for Drugs

Tramadol products

Coverage decision

L&I recognizes tramadol as an opioid. Payment for tramadol products including the combination with acetaminophen is subject to L&I's opioid rules and guidelines. This determination is made regardless of the risk level for potential abuse or whether it has "pure" opiate agonist properties.

Tramadol is a centrally acting analgesic medication. Its pharmacologic effect is due to the binding of both parent and metabolite, M1, to μ-opioid receptors as well as inhibiting the reuptake of norepinephrine and serotonin. As such, tramadol is recognized as an opiate agonist by the American Hospital Formulary Service (AHFS) Pharmacologic-Therapeutic Classification.

The Food and Drug Administration has approved the following tramadol products:

  • Ultram® (tramadol) is approved for management of moderate to moderately severe pain in adults.
  • Ultram ER® and Ryzolt® (tramadol extended-release) are indicated for management of moderate to moderately severe pain in adults who require around-the-clock treatment of pain for an extended period of time.
  • Ultracet® (tramadol with acetaminophen) is indicated for the short-term (5 days or less) management of acute pain.

For more information:
See Pharmacy Services' Opioid Rules site.

See WAC 296-20-03019 through 296-20-03023 for payment of opioids to treat chronic, noncancer pain.

End of main content, page footer follows.

Access Washington official state portal

  © Washington State Dept. of Labor & Industries. Use of this site is subject to the laws of the state of Washington.

Help us improve